 | • レポートコード：MRC2312MG01540 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、76ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の抗放射線薬市場規模と予測を収録しています。・世界の抗放射線薬市場：売上、2018年-2023年、2024年-2029年 ・世界の抗放射線薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の抗放射線薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ヨウ化カリウム（KI）」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 抗放射線薬のグローバル主要企業は、Amgen、 Anbex、 BTG International、 Cellphire、 Chrysalis BioTherapeutics、 Darnitsa、 Enzychem Lifesciences、 Humanetics、 Mission Pharmacal、 Partner Therapeutics、 Myelo Therapeutics、 Pluriなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、抗放射線薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の抗放射線薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の抗放射線薬市場：タイプ別市場シェア、2022年 ・ヨウ化カリウム（KI）、プルシアンブルー、DTPA（ジエチレントリアミン五酢酸）、その他 世界の抗放射線薬市場：用途別、2018年-2023年、2024年-2029年 世界の抗放射線薬市場：用途別市場シェア、2022年 ・急性放射線症候群（ARS）、がん治療、放射線被曝、その他 世界の抗放射線薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の抗放射線薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における抗放射線薬のグローバル売上、2018年-2023年 ・主要企業における抗放射線薬のグローバル売上シェア、2022年 ・主要企業における抗放射線薬のグローバル販売量、2018年-2023年 ・主要企業における抗放射線薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Amgen、 Anbex、 BTG International、 Cellphire、 Chrysalis BioTherapeutics、 Darnitsa、 Enzychem Lifesciences、 Humanetics、 Mission Pharmacal、 Partner Therapeutics、 Myelo Therapeutics、 Pluri ************************************************************* ・調査・分析レポートの概要 抗放射線薬市場の定義 市場セグメント 世界の抗放射線薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の抗放射線薬市場規模 世界の抗放射線薬市場規模：2022年 VS 2029年 世界の抗放射線薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの抗放射線薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の抗放射線薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：ヨウ化カリウム（KI）、プルシアンブルー、DTPA（ジエチレントリアミン五酢酸）、その他 抗放射線薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：急性放射線症候群（ARS）、がん治療、放射線被曝、その他 抗放射線薬の用途別グローバル売上・予測 ・地域別市場分析 地域別抗放射線薬市場規模 2022年と2029年 地域別抗放射線薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Amgen、 Anbex、 BTG International、 Cellphire、 Chrysalis BioTherapeutics、 Darnitsa、 Enzychem Lifesciences、 Humanetics、 Mission Pharmacal、 Partner Therapeutics、 Myelo Therapeutics、 Pluri ... |
This research report provides a comprehensive analysis of the Anti-radiation Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Anti-radiation Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Anti-radiation Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Anti-radiation Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Anti-radiation Drugs market presents opportunities for various stakeholders, including Acute Radiation Syndrome(ARS), Cancer Treatment. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Anti-radiation Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Anti-radiation Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Anti-radiation Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Anti-radiation Drugs market.
Market Overview: The report provides a comprehensive overview of the Anti-radiation Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Potassium lodide (KI), Prussian Blue), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Anti-radiation Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Anti-radiation Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Anti-radiation Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Anti-radiation Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Anti-radiation Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Anti-radiation Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Anti-radiation Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Anti-radiation Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Anti-radiation Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Potassium lodide (KI)
Prussian Blue
DTPA (Diethylenetriamine Pentaacetate)
Others
Market segment by Application
Acute Radiation Syndrome(ARS)
Cancer Treatment
Radiation Exposure
Others
Global Anti-radiation Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Amgen
Anbex
BTG International
Cellphire
Chrysalis BioTherapeutics
Darnitsa
Enzychem Lifesciences
Humanetics
Mission Pharmacal
Partner Therapeutics
Myelo Therapeutics
Pluri
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-radiation Drugs, market overview.
Chapter 2: Global Anti-radiation Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Anti-radiation Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-radiation Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Anti-radiation Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Anti-radiation Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-radiation Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-radiation Drugs Overall Market Size
2.1 Global Anti-radiation Drugs Market Size: 2022 VS 2029
2.2 Global Anti-radiation Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Anti-radiation Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Anti-radiation Drugs Players in Global Market
3.2 Top Global Anti-radiation Drugs Companies Ranked by Revenue
3.3 Global Anti-radiation Drugs Revenue by Companies
3.4 Global Anti-radiation Drugs Sales by Companies
3.5 Global Anti-radiation Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Anti-radiation Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Anti-radiation Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Anti-radiation Drugs Players in Global Market
3.8.1 List of Global Tier 1 Anti-radiation Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Anti-radiation Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Anti-radiation Drugs Market Size Markets, 2022 & 2029
4.1.2 Potassium lodide (KI)
4.1.3 Prussian Blue
4.1.4 DTPA (Diethylenetriamine Pentaacetate)
4.1.5 Others
4.2 By Type – Global Anti-radiation Drugs Revenue & Forecasts
4.2.1 By Type – Global Anti-radiation Drugs Revenue, 2018-2023
4.2.2 By Type – Global Anti-radiation Drugs Revenue, 2024-2029
4.2.3 By Type – Global Anti-radiation Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Anti-radiation Drugs Sales & Forecasts
4.3.1 By Type – Global Anti-radiation Drugs Sales, 2018-2023
4.3.2 By Type – Global Anti-radiation Drugs Sales, 2024-2029
4.3.3 By Type – Global Anti-radiation Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Anti-radiation Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Anti-radiation Drugs Market Size, 2022 & 2029
5.1.2 Acute Radiation Syndrome(ARS)
5.1.3 Cancer Treatment
5.1.4 Radiation Exposure
5.1.5 Others
5.2 By Application – Global Anti-radiation Drugs Revenue & Forecasts
5.2.1 By Application – Global Anti-radiation Drugs Revenue, 2018-2023
5.2.2 By Application – Global Anti-radiation Drugs Revenue, 2024-2029
5.2.3 By Application – Global Anti-radiation Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Anti-radiation Drugs Sales & Forecasts
5.3.1 By Application – Global Anti-radiation Drugs Sales, 2018-2023
5.3.2 By Application – Global Anti-radiation Drugs Sales, 2024-2029
5.3.3 By Application – Global Anti-radiation Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Anti-radiation Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Anti-radiation Drugs Market Size, 2022 & 2029
6.2 By Region – Global Anti-radiation Drugs Revenue & Forecasts
6.2.1 By Region – Global Anti-radiation Drugs Revenue, 2018-2023
6.2.2 By Region – Global Anti-radiation Drugs Revenue, 2024-2029
6.2.3 By Region – Global Anti-radiation Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Anti-radiation Drugs Sales & Forecasts
6.3.1 By Region – Global Anti-radiation Drugs Sales, 2018-2023
6.3.2 By Region – Global Anti-radiation Drugs Sales, 2024-2029
6.3.3 By Region – Global Anti-radiation Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Anti-radiation Drugs Revenue, 2018-2029
6.4.2 By Country – North America Anti-radiation Drugs Sales, 2018-2029
6.4.3 US Anti-radiation Drugs Market Size, 2018-2029
6.4.4 Canada Anti-radiation Drugs Market Size, 2018-2029
6.4.5 Mexico Anti-radiation Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Anti-radiation Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Anti-radiation Drugs Sales, 2018-2029
6.5.3 Germany Anti-radiation Drugs Market Size, 2018-2029
6.5.4 France Anti-radiation Drugs Market Size, 2018-2029
6.5.5 U.K. Anti-radiation Drugs Market Size, 2018-2029
6.5.6 Italy Anti-radiation Drugs Market Size, 2018-2029
6.5.7 Russia Anti-radiation Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Anti-radiation Drugs Market Size, 2018-2029
6.5.9 Benelux Anti-radiation Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Anti-radiation Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Anti-radiation Drugs Sales, 2018-2029
6.6.3 China Anti-radiation Drugs Market Size, 2018-2029
6.6.4 Japan Anti-radiation Drugs Market Size, 2018-2029
6.6.5 South Korea Anti-radiation Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Anti-radiation Drugs Market Size, 2018-2029
6.6.7 India Anti-radiation Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Anti-radiation Drugs Revenue, 2018-2029
6.7.2 By Country – South America Anti-radiation Drugs Sales, 2018-2029
6.7.3 Brazil Anti-radiation Drugs Market Size, 2018-2029
6.7.4 Argentina Anti-radiation Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Anti-radiation Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Anti-radiation Drugs Sales, 2018-2029
6.8.3 Turkey Anti-radiation Drugs Market Size, 2018-2029
6.8.4 Israel Anti-radiation Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Anti-radiation Drugs Market Size, 2018-2029
6.8.6 UAE Anti-radiation Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Amgen
7.1.1 Amgen Company Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Anti-radiation Drugs Major Product Offerings
7.1.4 Amgen Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Amgen Key News & Latest Developments
7.2 Anbex
7.2.1 Anbex Company Summary
7.2.2 Anbex Business Overview
7.2.3 Anbex Anti-radiation Drugs Major Product Offerings
7.2.4 Anbex Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Anbex Key News & Latest Developments
7.3 BTG International
7.3.1 BTG International Company Summary
7.3.2 BTG International Business Overview
7.3.3 BTG International Anti-radiation Drugs Major Product Offerings
7.3.4 BTG International Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.3.5 BTG International Key News & Latest Developments
7.4 Cellphire
7.4.1 Cellphire Company Summary
7.4.2 Cellphire Business Overview
7.4.3 Cellphire Anti-radiation Drugs Major Product Offerings
7.4.4 Cellphire Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Cellphire Key News & Latest Developments
7.5 Chrysalis BioTherapeutics
7.5.1 Chrysalis BioTherapeutics Company Summary
7.5.2 Chrysalis BioTherapeutics Business Overview
7.5.3 Chrysalis BioTherapeutics Anti-radiation Drugs Major Product Offerings
7.5.4 Chrysalis BioTherapeutics Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Chrysalis BioTherapeutics Key News & Latest Developments
7.6 Darnitsa
7.6.1 Darnitsa Company Summary
7.6.2 Darnitsa Business Overview
7.6.3 Darnitsa Anti-radiation Drugs Major Product Offerings
7.6.4 Darnitsa Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Darnitsa Key News & Latest Developments
7.7 Enzychem Lifesciences
7.7.1 Enzychem Lifesciences Company Summary
7.7.2 Enzychem Lifesciences Business Overview
7.7.3 Enzychem Lifesciences Anti-radiation Drugs Major Product Offerings
7.7.4 Enzychem Lifesciences Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Enzychem Lifesciences Key News & Latest Developments
7.8 Humanetics
7.8.1 Humanetics Company Summary
7.8.2 Humanetics Business Overview
7.8.3 Humanetics Anti-radiation Drugs Major Product Offerings
7.8.4 Humanetics Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Humanetics Key News & Latest Developments
7.9 Mission Pharmacal
7.9.1 Mission Pharmacal Company Summary
7.9.2 Mission Pharmacal Business Overview
7.9.3 Mission Pharmacal Anti-radiation Drugs Major Product Offerings
7.9.4 Mission Pharmacal Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Mission Pharmacal Key News & Latest Developments
7.10 Partner Therapeutics
7.10.1 Partner Therapeutics Company Summary
7.10.2 Partner Therapeutics Business Overview
7.10.3 Partner Therapeutics Anti-radiation Drugs Major Product Offerings
7.10.4 Partner Therapeutics Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Partner Therapeutics Key News & Latest Developments
7.11 Myelo Therapeutics
7.11.1 Myelo Therapeutics Company Summary
7.11.2 Myelo Therapeutics Business Overview
7.11.3 Myelo Therapeutics Anti-radiation Drugs Major Product Offerings
7.11.4 Myelo Therapeutics Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Myelo Therapeutics Key News & Latest Developments
7.12 Pluri
7.12.1 Pluri Company Summary
7.12.2 Pluri Business Overview
7.12.3 Pluri Anti-radiation Drugs Major Product Offerings
7.12.4 Pluri Anti-radiation Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Pluri Key News & Latest Developments
8 Global Anti-radiation Drugs Production Capacity, Analysis
8.1 Global Anti-radiation Drugs Production Capacity, 2018-2029
8.2 Anti-radiation Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Anti-radiation Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Anti-radiation Drugs Supply Chain Analysis
10.1 Anti-radiation Drugs Industry Value Chain
10.2 Anti-radiation Drugs Upstream Market
10.3 Anti-radiation Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Anti-radiation Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
